A detailed history of Birchview Capital, LP transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 211,200 shares of BLUE stock, worth $63,360. This represents 0.1% of its overall portfolio holdings.

Number of Shares
211,200
Previous 311,200 32.13%
Holding current value
$63,360
Previous $304,000 64.14%
% of portfolio
0.1%
Previous 0.3%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.47 - $1.35 $47,000 - $135,000
-100,000 Reduced 32.13%
211,200 $109,000
Q2 2024

Aug 13, 2024

SELL
$0.85 - $1.26 $8,500 - $12,600
-10,000 Reduced 3.11%
311,200 $304,000
Q1 2024

May 14, 2024

SELL
$0.91 - $1.75 $121,940 - $234,500
-134,000 Reduced 29.44%
321,200 $411,000
Q3 2023

Nov 14, 2023

BUY
$3.02 - $4.05 $622,120 - $834,300
206,000 Added 82.66%
455,200 $1.38 Million
Q2 2023

Aug 08, 2023

BUY
$2.79 - $5.03 $139,500 - $251,500
50,000 Added 25.1%
249,200 $819,000
Q1 2023

May 12, 2023

BUY
$3.14 - $8.22 $317,768 - $831,864
101,200 Added 103.27%
199,200 $633,000
Q2 2022

Aug 12, 2022

BUY
$2.94 - $5.23 $41,160 - $73,220
14,000 Added 16.67%
98,000 $406,000
Q3 2021

Nov 12, 2021

BUY
$11.24 - $21.0 $112,400 - $210,000
10,000 Added 13.51%
84,000 $1.61 Million
Q2 2021

Aug 10, 2021

SELL
$18.04 - $22.09 $27,060 - $33,135
-1,500 Reduced 1.99%
74,000 $2.37 Million
Q1 2021

May 14, 2021

BUY
$16.59 - $33.89 $223,965 - $457,515
13,500 Added 21.77%
75,500 $2.28 Million
Q4 2020

Feb 09, 2021

BUY
$27.5 - $37.92 $55,000 - $75,840
2,000 Added 3.33%
62,000 $2.68 Million
Q2 2020

Aug 10, 2020

BUY
$27.12 - $45.97 $1.63 Million - $2.76 Million
60,000 New
60,000 $3.66 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $23.1M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Birchview Capital, LP Portfolio

Follow Birchview Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.